Use of infliximab and other biologics in Behçet disease

Intern Med J. 2014 Jan;44(1):96-100. doi: 10.1111/imj.12297.

Abstract

Behçet disease is a multisystem vasculitis characterised by recurrent oral ulceration in conjunction with other manifestations. Neurological involvement or neuro-Behçet disease is not common, but typically affects young men at its onset between the ages of 20 and 40 with significant long-term morbidity and mortality. There is substantial case literature to support the use of tumour necrosis factor antagonists, notably infliximab, in the treatment of neuro-Behçet disease.

Keywords: Behçet disease; infliximab; neuro-Behçet.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Behcet Syndrome / complications
  • Behcet Syndrome / diagnosis
  • Behcet Syndrome / drug therapy*
  • Behcet Syndrome / epidemiology
  • Behcet Syndrome / therapy
  • Biological Products / therapeutic use*
  • Combined Modality Therapy
  • Delayed Diagnosis
  • Disease Progression
  • HLA-B51 Antigen / analysis
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Infliximab
  • Male
  • Methylprednisolone / therapeutic use
  • Mobility Limitation
  • Paraparesis / etiology
  • Paraparesis / rehabilitation
  • Plasmapheresis
  • Prednisolone / therapeutic use
  • Remission Induction
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Biological Products
  • HLA-B51 Antigen
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • Prednisolone
  • Infliximab
  • Methylprednisolone